BMEA vs FSP Comparison

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.